Top Markets
#1 MowCat MowCat +369.14%
#2 龙虾 (Lobster) 龙虾 (Lobster) +66.90%
#3 SODAX SODAX +51.90%
#4 Cortex Cortex +33.34%
#5 DexNet DexNet +23.19%
#6 OpenEden OpenEden +21.97%
#7 BNB Attestation Service BNB Attestation Service +20.72%
#8 Magma Finance Magma Finance +16.49%
#9 wojak wojak +16.15%
#10 Akedo Akedo +16.13%
Coin of the day
MowCat MowCat
Settings
Language
ENGLISH
Currency
USD
Theme
Avalyn Pharma Inc. Common Stock Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc. Common Stock

AVLN
Rank in Stocks #7326
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its... Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Share Price
$36.75
Last synced: 2026-08-27
Market Cap
$1.63B
Change (1 day)
-0.78%
Change (1 year)
-
Country
US
Trade Avalyn Pharma Inc. Common Stock (AVLN)

Category

Healthcare
P/E ratio for Avalyn Pharma Inc. Common Stock (AVLN)
P/E ratio as of 2026 TTM: 0
According to Avalyn Pharma Inc. Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Avalyn Pharma Inc. Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.